Videos
DREAMM2.jpg'/>dreamm-2-single-agent-belantamab-mafodotin-patients-relapsed-refractory-multiple-myeloma' />What is the DREAMM-2 Trial?DREAMM-2 is an open-label study of belantamab mafodotin. Patients in the trial had actively progressing multiple myeloma that had worsened…
June 10, 2020
Videos
What is the DREAMM-6 trial?The DREAMM-6 trial studies belantamab mafodotin (Bela), a B-cell maturation antigen targeting immunoconjugate. Bela has demonstrated clinically meaningful, single-agent activity in patients with heavily pre-treated relapsed refractory multiple myeloma (RRMM…
June 10, 2020
Videos
What is the DREAMM-5 platform trial?The DREAMM-5 platform trials studies the single-agent belantamab mafodotin (GSK2857916), a B-cell maturation antigen targeting immunoconjugates.In this video:Dr. Paul G. Richardson (Dana Farber Cancer Institute — Boston) explains that belantamab…
June 15, 2020
Videos
What is the DREAMM-9 trial?The DREAMM-9 trial is a phase III study of bortezomib, lenalidomide, and dexamethasone (VRd) as the standard of care for transplant-eligible and transplant-ineligible newly diagnosed multiple myeloma patients. Yet, relapse is usually inevitable.In…
June 15, 2020